New combo attack on pancreatic cancer: freeze and boost immunity
NCT ID NCT07306286
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a two-pronged approach for locally advanced pancreatic cancer that has stopped responding to standard chemotherapy. First, doctors freeze the tumor using cryoablation, then give patients an experimental antibody called Apalulizumab that targets two immune checkpoints (PD-1 and CTLA-4) to help the immune system fight the cancer. The study aims to see if this combination improves overall survival and progression-free survival in 20 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Apalulizumab (a dual-function antibody targeting PD-1 and CTLA-4) and cryoablation (a procedure that freezes tumors)
- What this could lead to
- If successful, this combination could offer a new second-line treatment option for patients with locally advanced pancreatic cancer who have not responded to standard chemotherapy.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The combination therapy also carries risks from both the freezing procedure and immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA LOCALLY ADVANCED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 2000010, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.